AR105114A1 - Compuestos de aminopiridina sustituida con heteroarilo - Google Patents

Compuestos de aminopiridina sustituida con heteroarilo

Info

Publication number
AR105114A1
AR105114A1 ARP160101893A ARP160101893A AR105114A1 AR 105114 A1 AR105114 A1 AR 105114A1 AR P160101893 A ARP160101893 A AR P160101893A AR P160101893 A ARP160101893 A AR P160101893A AR 105114 A1 AR105114 A1 AR 105114A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
cycloalkyl
heteroaryl
oxetanyl
Prior art date
Application number
ARP160101893A
Other languages
English (en)
Inventor
Rao Polimera Subba
Kumar Sistla Ramesh
Sarkunam Kandhasamy
Reddy Paidi Venkatram
Kesavan Nair Satheesh
Wu Hong
B Santella Joseph
E Macor John
Hynes John
s gardner Daniel
V Duncia John
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR105114A1 publication Critical patent/AR105114A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado por la fórmula (1) o una sal de aquel, en donde: HET es un heteroarilo seleccionado de imidazo[1,2-b]piridazinilo y pirazolo[1,5-a]pirimidinilo, en donde el heteroarilo está unido al grupo piridinilo en el compuesto de la fórmula (1) mediante un átomo del anillo de carbono en el heteroarilo, y en donde el heteroarilo se sustituye con 0 a 2 Rᵇ; A es pirazolilo, imidazolilo o triazolilo, cada uno sustituido con 0 ó 1 Rᵃ; R³ es: (i) -CH₂CH₃, -CH(CH₃)₂, -CH₂CHF₂, -CH(CH₃)CH₂OH, oxetanilo, tetrahidropiranilo o C₃₋₅ cicloalquilo sustituido con 0 a 2 F; (ii) pirazolilo sustituido con 0 a 2 sustituyentes seleccionados independientemente de C₁₋₃ alquilo, C₁₋₃ hidroxialquilo, C₁₋₃ fluoroalquilo, oxetanilo, tetrahidrofuranilo y tetrahidropiranilo; Rᵃ es: (i) F, Cl, -OH, -CN, C₁₋₆ alquilo, C₁₋₄ fluoroalquilo, C₁₋₄ cianoalquilo o C₁₋₆ hidroxialquilo; o (ii) C₃₋₆ cicloalquilo, azetidinilo, oxetanilo, tetrahidrofuranilo, tetrahidropiranilo, piperidinilo, piperazinilo, pirrolilo, pirrolidinonilo, morfolinilo, pirrolidinilo, fenilo, pirazolilo, imidazolilo, piridinilo o pirimidinilo, cada uno sustituido con 0 a 4 sustituyentes seleccionados independientemente de F, -CN, -OH, -NRʸRʸ, C₁₋₃ alquilo, C₁₋₃ fluoroalquilo, -CH(fenilo)₂, -O(C₁₋₄ alquilo), -C(O)(C₁₋₄ alquilo), -C(O)(C₁₋₄ deuteroalquilo), -C(O)(C₃₋₆ cicloalquilo), -C(O)O(C₁₋₄ alquilo), -C(O)NRʸRʸ, -C(O)(fenilo), -C(O)(piridinilo), -C(O)CH₂(C₃₋₆ cicloalquilo), -NHC(O)CH₃, -NHC(O)OCH₃, -NHC(O)OC(CH₃)₃, -S(O)₂(C₁₋₃ alquilo) y -OS(O)₂(C₁₋₃ alquilo); cada Rᵇ se selecciona independientemente de F, Cl, -CN, NH₂, -CH₃, -OCH₃ y ciclopropilo; y cada Rʸ es independientemente H o C₁₋₃ alquilo.
ARP160101893A 2015-06-24 2016-06-23 Compuestos de aminopiridina sustituida con heteroarilo AR105114A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1880DE2015 2015-06-24

Publications (1)

Publication Number Publication Date
AR105114A1 true AR105114A1 (es) 2017-09-06

Family

ID=56345252

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101893A AR105114A1 (es) 2015-06-24 2016-06-23 Compuestos de aminopiridina sustituida con heteroarilo

Country Status (9)

Country Link
US (1) US10202390B2 (es)
EP (1) EP3313844B1 (es)
JP (1) JP6720225B2 (es)
CN (1) CN108026099B (es)
AR (1) AR105114A1 (es)
ES (1) ES2822956T3 (es)
TW (1) TW201713663A (es)
UY (1) UY36747A (es)
WO (1) WO2016210037A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3313844B1 (en) 2015-06-24 2020-08-26 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
EP3313840B1 (en) 2015-06-24 2019-07-24 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
UY36749A (es) * 2015-06-24 2016-12-30 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
MX2019012929A (es) 2017-05-11 2020-01-14 Bristol Myers Squibb Co Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4).
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
TWI727392B (zh) 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
JP7169429B2 (ja) 2018-08-13 2022-11-10 ギリアード サイエンシーズ， インコーポレイテッド ＩＲＡＫ４阻害剤としてのピロロ［１，２－ｂ］ピリダジン誘導体
AU2019321267B2 (en) * 2018-08-13 2022-07-14 Gilead Sciences, Inc. Pyrrolo[1,2-b]pyridazine derivatives as IRAK4 inhibitors
KR20220035447A (ko) * 2019-07-18 2022-03-22 브리스톨-마이어스 스큅 컴퍼니 IRAK4 억제제로서 유용한 피라졸로[3,4-d]피롤로[1,2-b]피리다지닐 화합물
WO2021016289A1 (en) * 2019-07-23 2021-01-28 Bristol-Myers Squibb Company Thienopyridinyl and thiazolopyridinyl compounds useful as irak4 inhibitors
KR20220155295A (ko) * 2020-02-19 2022-11-22 누릭스 테라퓨틱스 인코포레이티드 인터류킨-1 수용체 관련 키나아제의 이작용성 분해제 및 이의 치료적 용도
CN113149995A (zh) * 2021-03-31 2021-07-23 安徽驱石医药科技有限公司 一种7-氟吡唑并[1,2-b]吡嗪-4-甲腈的合成方法及应用
AU2022330009A1 (en) 2021-08-18 2024-01-25 Gilead Sciences, Inc. Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE432929T1 (de) 2001-06-15 2009-06-15 Vertex Pharma 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
MXPA04012855A (es) 2002-06-28 2005-04-19 Yamanouchi Pharma Co Ltd Derivado de diaminopirimidincarboxiamida.
BRPI0406809A (pt) 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
CN1820001A (zh) 2003-07-10 2006-08-16 神经能质公司 经取代的杂环二芳基胺类似物
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP2063962A2 (en) * 2006-09-07 2009-06-03 Biogen Idec MA Inc. Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
US8273759B2 (en) 2007-06-08 2012-09-25 Bayer Cropscience Ag Fungicide heterocyclyl-pyrimidinyl-amino derivatives
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
JPWO2010058846A1 (ja) 2008-11-21 2012-04-19 アステラス製薬株式会社 ４，６−ジアミノニコチンアミド化合物
AU2009320683B2 (en) 2008-11-28 2012-07-19 Kowa Company, Ltd. Pyridine-3-carboxyamide derivative
EP2440204B1 (en) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
WO2011053701A1 (en) 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv Phenoxy-substituted pyrimidines as opioid receptor modulators
CN102971304A (zh) 2010-02-01 2013-03-13 日本化学医药株式会社 Gpr119激动剂
EP2702064A4 (en) 2011-04-29 2014-10-08 Icahn School Med Mount Sinai Kinase Inhibitors
JP6109195B2 (ja) 2012-01-13 2017-04-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ キナーゼ阻害剤として有用な複素環置換されたピリジル化合物
ES2575604T3 (es) 2012-01-13 2016-06-29 Bristol-Myers Squibb Company Compuestos de piridilo sustituidos con tiazolilo o tiadiazolilo útiles como inhibidores cinasa
US8987311B2 (en) 2012-01-13 2015-03-24 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
US9546153B2 (en) 2012-11-08 2017-01-17 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
BR112015009850A2 (pt) * 2012-11-08 2017-07-11 Bristol Myers Squibb Co compostos de piridila substituídos por heteroarila úteis como moduladores de quinase
KR102233252B1 (ko) 2012-11-08 2021-03-26 브리스톨-마이어스 스큅 컴퍼니 ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
UY35935A (es) * 2014-01-03 2015-06-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4
EP3313844B1 (en) 2015-06-24 2020-08-26 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
EP3313840B1 (en) 2015-06-24 2019-07-24 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds

Also Published As

Publication number Publication date
CN108026099B (zh) 2020-07-10
US10202390B2 (en) 2019-02-12
JP2018524331A (ja) 2018-08-30
WO2016210037A1 (en) 2016-12-29
JP6720225B2 (ja) 2020-07-08
US20180179213A1 (en) 2018-06-28
EP3313844A1 (en) 2018-05-02
TW201713663A (zh) 2017-04-16
CN108026099A (zh) 2018-05-11
UY36747A (es) 2016-12-30
EP3313844B1 (en) 2020-08-26
ES2822956T3 (es) 2021-05-05

Similar Documents

Publication Publication Date Title
AR105114A1 (es) Compuestos de aminopiridina sustituida con heteroarilo
AR105113A1 (es) Compuestos de aminopiridina sustituida con heteroarilo
AR101174A1 (es) Imidazopirazinas como inhibidores de lsd1
AR105112A1 (es) Compuestos de aminopiridina sustituida con heteroarilo
AR101175A1 (es) Imidazopiridinas e imidazopirazinas como inhibidores de lsd1
AR098991A1 (es) Compuestos de nicotinamida sustituida con heteroarilo
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
PE20160540A1 (es) Inhibidores de bromodominios
EA202192151A1 (ru) Применение пиразолпиримидиновых производных для лечения нарушений, связанных с pi3k
AR103064A1 (es) Compuestos moduladores de fxr (nr1h4)
AR102204A1 (es) Compuestos derivados de amino-alquilbenzotiazepinas
ME02423B (me) 1-(3,3-DIMETILBUTIL)-3-(2-FLUOR-4-METIL-5-(7-METIL-2-(METILAMINO)PIRIDO[2,3-d]PIRIMIDIN-6-IL)FENIL)UREA KAO INHIBITOR Raf KINAZE U LIJEČENJU RAKA
MX371312B (es) Pirazolil-ureas como inhibidores de quinasas.
AR092876A1 (es) Inhibidores no nucleosidos de la transcriptasa inversa
AR088235A1 (es) Derivados de pirazoloquinolina
AR091285A1 (es) Inhibidores de bromodominio y sus usos
SI3357922T1 (sl) 2-((5-(1-(3-(metilsulfonil)propil)piperidin-4-il)piridin-2-il)amino) pirido(2,3-D)pirimidin-7(8H)-on derivati in sorodne spojine kot CDK4 inhibitorji za zdravljenje tumorjev
AR107042A1 (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
AR089776A1 (es) 5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir
PH12016502147A1 (en) Substituted 4-phenylpiperidines, their preparation and use
AR094565A1 (es) Compuestos y métodos para tratar infecciones bacterianas
EA202091761A1 (ru) Комбинированная терапия для лечения гастроинтестинальных стромальных опухолей
AR095267A1 (es) Compuestos inhibidores de la fosfodiesterasa del tipo 10a
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
MX365851B (es) Compuestos de benzofurazano anti-amiloides y metodos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure